Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elke Rist

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos One|January 30, 2014
Cell-type specific four-component hydrogelTimo Aberle, Katrin Franke, Elke Rist, et al.
Cell and Tissue Research|April 30, 2015
miR-124 disinhibits neurite outgrowth in an inflammatory environmentHanna Hartmann, Kristin Hoehne, Elke Rist, et al.
Journal of Hepatology|March 11, 2023
MYC determines lineage commitment in KRAS-driven primary liver cancer developmentLuana D'Artista, Athina Anastasia Moschopoulou, Iros Barozzi, et al.
Nature Cancer|January 17, 2025
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancerRamona Rudalska, Jule Harbig, Michael Forster, et al.
Cell|March 15, 2024
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failureStefan Zwirner, Anan A Abu Rmilah, Sabrina Klotz, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos One|January 30, 2014
Cell-type specific four-component hydrogelTimo Aberle, Katrin Franke, Elke Rist, et al.
Cell and Tissue Research|April 30, 2015
miR-124 disinhibits neurite outgrowth in an inflammatory environmentHanna Hartmann, Kristin Hoehne, Elke Rist, et al.
Journal of Hepatology|March 11, 2023
MYC determines lineage commitment in KRAS-driven primary liver cancer developmentLuana D'Artista, Athina Anastasia Moschopoulou, Iros Barozzi, et al.
Nature Cancer|January 17, 2025
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancerRamona Rudalska, Jule Harbig, Michael Forster, et al.
Cell|March 15, 2024
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failureStefan Zwirner, Anan A Abu Rmilah, Sabrina Klotz, et al.
Pageof 1